G1 Therapeutics (GTHX) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of G1 Therapeutics (NASDAQ:GTHX) from a sell rating to a hold rating in a research report released on Tuesday morning.

According to Zacks, “G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company’s product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC. “

A number of other research firms also recently weighed in on GTHX. Wedbush reissued an outperform rating and set a $67.00 target price on shares of G1 Therapeutics in a report on Thursday, December 20th. Raymond James assumed coverage on G1 Therapeutics in a report on Wednesday, December 19th. They set a strong-buy rating for the company. BidaskClub downgraded G1 Therapeutics from a hold rating to a sell rating in a report on Tuesday, December 18th. Cowen reissued a buy rating on shares of G1 Therapeutics in a report on Wednesday, March 6th. Finally, B. Riley assumed coverage on G1 Therapeutics in a report on Thursday, February 7th. They set a buy rating and a $55.00 target price for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. G1 Therapeutics has an average rating of Buy and an average target price of $66.00.

GTHX opened at $15.70 on Tuesday. G1 Therapeutics has a fifty-two week low of $15.21 and a fifty-two week high of $69.57. The firm has a market cap of $620.99 million, a PE ratio of -6.13 and a beta of 2.37.

In other news, insider Rajesh Malik sold 3,776 shares of G1 Therapeutics stock in a transaction on Monday, December 17th. The stock was sold at an average price of $30.00, for a total transaction of $113,280.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Cynthia Schwalm purchased 1,420 shares of the company’s stock in a transaction that occurred on Wednesday, December 26th. The stock was bought at an average cost of $18.45 per share, with a total value of $26,199.00. The disclosure for this purchase can be found here. 15.92% of the stock is currently owned by company insiders.

A number of hedge funds have recently bought and sold shares of GTHX. Legal & General Group Plc raised its stake in G1 Therapeutics by 20.0% in the fourth quarter. Legal & General Group Plc now owns 4,060 shares of the company’s stock valued at $78,000 after purchasing an additional 676 shares in the last quarter. Meeder Asset Management Inc. raised its stake in G1 Therapeutics by 147.7% in the fourth quarter. Meeder Asset Management Inc. now owns 4,484 shares of the company’s stock valued at $87,000 after purchasing an additional 2,674 shares in the last quarter. Pacer Advisors Inc. acquired a new position in G1 Therapeutics in the third quarter valued at about $111,000. Metropolitan Life Insurance Co. NY raised its stake in G1 Therapeutics by 413.4% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 7,665 shares of the company’s stock valued at $147,000 after purchasing an additional 6,172 shares in the last quarter. Finally, WINTON GROUP Ltd acquired a new position in G1 Therapeutics in the third quarter valued at about $218,000. 75.08% of the stock is owned by institutional investors and hedge funds.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.

See Also: What is Put Option Volume?

Get a free copy of the Zacks research report on G1 Therapeutics (GTHX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.